There are many biotechnology companies that manage to gain the excitement of investors with the next revolutionary advancement in medicine. In reality, however, most of these companies are often a long, long way off to proving they will ever make it to an FDA authorized Phase III trial, much less commercialization. In fact, there are several billion-dollar market cap biotechs that come to mind that still haven't demonstrated safety. The CRISPR-Cas9 stock sector, the promising next big thing, is such an example. Editas Medicine Inc. (EDIT) and CRISPR Therapeutics AG (CRSP